Celcuity

$CELC reports financial results for Q1 2026 and provides a corporate update today. Press release: bit.ly/4npRb1G | Webcast at 4:30 pm ET: bit.ly/43ajaZY

$CELC announces updates to our clinical development plan including expansion of our Phase 3 VIKTORIA-2 clinical trial to include a second study evaluating gedatolisib as 1L treatment in patients with endocrine-sensitive HR+/HER2- advanced breast cancer. bit.ly/3P5iWQG

$CELC will report on Q1 2026 financial results next Thursday, May 14, 2026. Celcuity management will host a webcast conference call at 4:30 pm ET. Learn more: bit.ly/4uASQUF

Today, we announced positive topline results from the PIK3CA mutant cohort of the Phase 3 VIKTORIA-1 clinical trial evaluating gedatolisib plus fulvestrant with or without palbociclib in patients with HR+/HER2- PIK3CA mutant advanced breast cancer. bit.ly/4tKpBP0

Celcuity reports financial results for the fourth quarter and full year 2025 and provides corporate update: bit.ly/4bHFzSk Listen in to our webcast conference call today at 4:30 pm ET: bit.ly/4lNVOSu $CELC

$CELC will report on Q4 and full year 2025 financial results next Wednesday, March 25, 2026. Celcuity management will host a webcast conference call at 4:30 pm ET. Learn more: bit.ly/4uTNu87

Results from the Phase 3 VIKTORIA-1 trial were published in @JCO_ASCO. We would like to thank Dr. Sara Hurvitz for serving as a co-primary investigator and for helping us potentially bring this important therapy to patients. Read the manuscript: bit.ly/4uCIx3p

We are proud to announce publication in the Journal of Clinical Oncology of results from the Phase 3 VIKTORIA-1 clinical trial. Read more here: bit.ly/4ujOzWn $CELC #gedatolisib

Tune in tomorrow to listen to our fireside chat at the Leerink Global Healthcare Conference: bit.ly/4c6WAqY $CELC

Tune in tomorrow to listen to our fireside chat at the TD Cowen 46th Annual Health Care Conference: bit.ly/4qOFgKZ

We look forward to attending the upcoming investor conferences in March: TD Cowen 46th Annual Health Care Conference, Leerink Global Healthcare Conference, and the 2026 Jefferies Biotech on the Beach Summit. For more information: bit.ly/4cf7mvs $CELC

We are pleased to announce the appointment of Chip Romp to Celcuity’s Board of Directors. Mr. Romp brings over 25 years of experience in the pharmaceutical industry to $CELC, with an emphasis on leading commercial organizations in the oncology setting. bit.ly/4rSQPlw

Tune in tomorrow and listen to our fireside chat with Celcuity CEO, Brian Sullivan, and biotech research analyst, Brad Canino, at the Guggenheim Emerging Outlook: Biotech Summit 2026. Listen to the webcast: bit.ly/3NRO2dr

$CELC is participating in a fireside chat and hosting investor meetings at the upcoming Guggenheim Emerging Outlook: Biotech Summit 2026. Read more here: bit.ly/45QFxFM

$CELC is proud to announce the acceptance of our NDA for gedatolisib in HR+/HER2-/PIK3CA wild-type advanced breast cancer. Read more here: bit.ly/4sQ5sqI

#News: Celcuity Announces FDA Acceptance of New Drug Application for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer PR Here: ir.celcuity.com/press-releases/ #teamcelcuity #oncology #biotechnology

Yesterday, Dr. Barbara Pistilli presented additional subgroup analysis and safety data from the Phase 3 VIKTORIA-1 trial. View the presentation here: bit.ly/48LO6lM

At this year’s SABCS meeting, we will share new data for gedatolisib from the Phase 3 VICKTORIA -1 trial in patients with HR+/HER2-/PIK3CA-wild type advanced breast cancer in a rapid oral session. Read our press release: bit.ly/4pEJkOm

#News: Celcuity Presents Updated Results from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium PR Here: ir.celcuity.com/press-releases/ #teamcelcuity #oncology #biotechnology

#News: Celcuity to Present Updated Data from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium PR Here: ir.celcuity.com/press-releases/ #teamcelcuity #oncology #biotechnology